» Articles » PMID: 7706044

Identification of a Major Pathogenic Epitope in the Human IRBP Molecule Recognized by Mice of the H-2r Haplotype

Overview
Specialty Ophthalmology
Date 1995 Apr 1
PMID 7706044
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Mice of the H-2b, H-2k, and H-2r haplotypes develop experimental autoimmune uveoretinitis (EAU) after immunization with interphotoreceptor retinoid-binding protein (IRBP) of bovine or monkey origin. The purpose of this study was to identify putative pathogenic epitope(s) of IRBP and to establish their immunodominance within the IRBP molecule.

Methods: Overlapping 20-amino acid peptides, spanning the entire human IRBP molecule, were synthesized and used to immunize C57BL/10 (H-2b), B10.BR (H-2k), and B10.RIII (H-2r) mice. Bovine IRBP was used as a positive control. Experimental autoimmune uveoretinitis was examined by histopathology 21 days after immunization. Immunologic responses were assessed by delayed-type hypersensitivity (DH) and lymphocyte proliferation assays.

Results: Peptide 161-180, spanning the sequence SGIPYIISYLHPGNTILHVD, was found to be highly pathogenic for B10.RIII mice but not for the other strains. A dose-response curve showed that peptide 161-180 was maximally pathogenic at 50 micrograms, but incidence and scores were reduced at 10 micrograms. The truncated 13-mer 165-177 was also highly pathogenic (100 to 200 micrograms), suggesting that it contained the pathogenic epitope. Mice immunized with the peptide, or with whole IRBP, had positive DH and lymphocyte responses to the immunizing as well as to the reciprocal antigen. A cell line derived to peptide 161-180 was also pathogenic for B10.RIII mice after adoptive transfer and responded (proliferation) to native IRBP.

Conclusions: High incidence and high severity scores, as well as immunologic cross-recognition of peptide 161-180 and native IRBP in vivo and in vitro, suggest that this peptide contains a major epitope recognized as pathogenic by B10.RIII mice.

Citing Articles

Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.

Merzbach S, Schumacher-Klinger A, Klazas M, Hoffman A, Lazarovici P, Gilon C Invest Ophthalmol Vis Sci. 2025; 66(1):13.

PMID: 39775697 PMC: 11724373. DOI: 10.1167/iovs.66.1.13.


Optimization of determinant factors associated with the efficiency of experimental autoimmune uveitis induction in C57BL/6 mice.

Yang M, Yang Z, Huang J, Yu W, He X, Yuan M Ann Transl Med. 2023; 10(23):1274.

PMID: 36618787 PMC: 9816839. DOI: 10.21037/atm-22-2293.


The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.

Chong W, Mattapallil M, Raychaudhuri K, Bing S, Wu S, Zhong Y Immunity. 2020; 53(2):384-397.e5.

PMID: 32673565 PMC: 7362799. DOI: 10.1016/j.immuni.2020.06.022.


Interleukin 22 ameliorates neuropathology and protects from central nervous system autoimmunity.

Mattapallil M, Kielczewski J, Zarate-Blades C, St Leger A, Raychaudhuri K, Silver P J Autoimmun. 2019; 102:65-76.

PMID: 31080013 PMC: 6667188. DOI: 10.1016/j.jaut.2019.04.017.


Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.

Papotto P, Marengo E, Sardinha L, Carvalho K, de Carvalho A, Castillo-Mendez S PLoS One. 2017; 12(3):e0171822.

PMID: 28248972 PMC: 5331984. DOI: 10.1371/journal.pone.0171822.